ID	Description	GeneRatio	BgRatio	pvalue	p.adjust	qvalue	geneID	Count
WP5095	Overview of proinflammatory and profibrotic mediators	40/641	73/5963	1.19286629495747e-20	5.72575821579587e-18	4.64590030667647e-18	6356/6357/6361/6362/6347/6364/6370/10344/6348/6351/9560/1437/1440/2919/3627/6373/284340/2920/2921/6374/6372/4283/3458/3586/3589/3605/29949/3552/3553/3557/51561/11009/3569/4312/4314/4318/5008/5196/6696/7124	40
WP5055	Burn wound healing	37/641	93/5963	1.88369592245622e-13	4.52087021389492e-11	3.66824995425684e-11	8038/6347/57124/1277/1278/2919/3579/2162/2200/3082/3383/3552/3553/3569/3624/3853/23643/440823/4312/4322/4313/4314/4318/64332/64127/5159/6282/6280/6423/6678/7042/7043/7076/7097/51311/3371/7124	37
WP5115	Network map of SARS-CoV-2 signaling pathway	55/641	190/5963	1.54631927046359e-12	2.47411083274174e-10	2.00750221077729e-10	59272/183/335/341/8542/684/715/838/6356/6347/6364/10344/6348/6351/1234/1051/629/3426/5199/1294/2919/3627/2920/2921/6374/6372/4283/3577/3579/84985/3091/10964/8519/10410/3458/3586/3605/8807/3552/3553/3569/3699/3726/116844/64386/114548/4939/5196/5743/6288/6289/6403/5054/6772/7124	55
WP2806	Complement system	30/641	75/5963	3.26548050464431e-11	3.91857660557318e-09	3.17954680715368e-09	133/335/715/717/720/722/728/27202/958/1604/22918/629/3426/5199/2162/2214/2219/2357/2769/3383/3687/3689/5648/5329/6401/6402/6403/710/6696/7097	30
WP4891	COVID-19 adverse outcome pathway	11/641	13/5963	1.30417897002993e-09	1.25201181122873e-07	1.01588677665489e-07	59272/183/6347/6348/1440/3627/3586/3553/3559/3569/7124	11
WP3624	Lung fibrosis	22/641	52/5963	4.12138872892123e-09	3.29711098313698e-07	2.67528742052782e-07	6356/6347/6348/6351/1232/1051/1215/1437/1440/2920/57105/2252/26585/3082/3553/3569/4313/4318/5328/6696/7076/7124	22
WP691	Tamoxifen metabolism	12/641	17/5963	8.0427266478138e-09	5.5150125585009e-07	4.47490054088888e-07	1545/1557/1558/1559/1565/1576/2326/2328/6783/6822/54657/7364	12
WP619	Type II interferon signaling	17/641	34/5963	1.12042012494591e-08	6.72252074967546e-07	5.45467692407877e-07	4261/3627/4283/2633/3383/3433/3458/3553/3659/9636/4843/5698/8651/9021/6688/6772/6890	17
WP5088	Prostaglandin signaling	15/641	28/5963	2.48208770491672e-08	1.32378010928892e-06	1.07411982551951e-06	834/6347/6348/2919/3627/4283/3458/3605/3552/3553/3569/4318/114548/9536/7124	15
WP2882	Nuclear receptors meta-pathway	59/641	268/5963	3.27425882667261e-08	1.57164423680285e-06	1.27523764828302e-06	5243/1244/64240/64241/51129/335/345/8553/330/874/6347/6364/1545/1555/1557/1559/1576/1551/1907/9982/2938/2939/1839/3082/3458/3589/3553/3726/23764/4199/8431/9971/9970/5142/5743/6286/6319/5272/6514/6515/11182/115584/159963/6527/200010/11254/340024/6532/23657/8140/5552/27286/2040/6822/7042/7056/7124/54657/7364	59
WP5039	SARS-CoV-2 innate immunity evasion and cell-specific immune response	23/641	63/5963	5.21939956738698e-08	2.27755617485977e-06	1.84801707170639e-06	59272/6347/6348/6351/1437/2919/3627/6373/284340/2920/2921/6374/6372/4283/3579/3433/8519/3586/3569/3902/5196/6772/7124	23
WP2865	IL1 and megakaryocytes in obesity	13/641	23/5963	9.37519553504166e-08	3.75007821401666e-06	3.04282662102229e-06	6347/1232/2205/1839/3383/3458/3553/4318/114548/7941/6280/7076/7097	13
WP455	GPCRs, class A rhodopsin-like	33/641	118/5963	1.30408436849463e-07	4.81508074521095e-06	3.90697341168432e-06	51554/134/27202/1230/2826/1232/1234/1237/10803/3577/3579/57105/1909/2151/2867/2357/2358/29909/2828/8111/8843/3274/3352/4543/64106/4888/53829/5031/5724/5737/5739/6752/56670	33
WP2328	Allograft rejection	25/641	76/5963	1.47649340159564e-07	4.84558786612808e-06	3.93172699663901e-06	5243/717/720/721/958/1604/941/1493/6373/4283/50943/10578/3002/3119/3134/3458/3586/3605/3552/3553/3559/120892/5551/6772/7124	25
WP5198	Inflammatory bowel disease signaling	16/641	35/5963	1.51424620816503e-07	4.84558786612808e-06	3.93172699663901e-06	50943/3458/3586/3594/3595/8807/3552/50615/51561/3569/4094/64127/6772/30009/7097/7124	16
WP129	Matrix metalloproteinases	13/641	24/5963	1.84589862256001e-07	5.53769586768003e-06	4.49330585754739e-06	4312/4319/4321/4322/4327/4313/10893/64386/4314/4316/4318/7076/7124	13
WP1533	Vitamin B12 metabolism	16/641	37/5963	3.9037604435251e-07	1.09346611373676e-05	8.87242241409212e-06	335/338/875/6347/8029/3383/3458/3553/3569/3949/6288/6289/5054/6648/6947/7124	16
WP3617	Photodynamic therapy-induced NF-kB survival signaling	15/641	33/5963	4.10049792651284e-07	1.09346611373676e-05	8.87242241409212e-06	597/330/1437/2920/3383/3552/3553/3569/4312/4313/4314/4318/5743/6401/7124	15
WP530	Cytokines and inflammatory response	11/641	19/5963	6.86268929859723e-07	1.73373203332983e-05	1.40675625511411e-05	1437/1440/2919/2920/3458/3586/3589/3552/3553/3569/7124	11
WP4754	IL-18 signaling pathway	51/641	239/5963	8.16663022129727e-07	1.95999125311135e-05	1.59034377993684e-05	321/467/330/6362/6347/6364/6348/6351/1051/9076/24146/6900/1277/1278/1281/2920/2921/338442/3383/3458/3586/8807/3553/3559/3569/3659/3801/4312/4322/4313/4314/4318/4688/64332/4843/8431/7941/5743/6004/8698/9021/6696/30009/7052/7076/7124/7127/4982/79931/7185/80149	51
WP15	Selenium micronutrient network	20/641	59/5963	1.53816465895522e-06	3.51580493475478e-05	2.8527364602177e-05	240/335/338/875/6347/1734/3383/3458/3553/3569/8564/8942/3949/5743/6288/6289/5054/6648/7124/7498	20
WP2877	Vitamin D receptor pathway	35/641	143/5963	1.80408662082321e-06	3.86957233181066e-05	3.13978456747795e-05	5243/240/248/768/838/875/958/634/1493/1594/1555/1559/1565/1576/168002/1673/50486/3091/3488/3726/5653/639/6273/6279/6280/10568/6696/6699/79689/412/6822/7042/7056/4982/54210	35
WP4462	Platelet-mediated interactions with vascular and circulating cells	10/641	17/5963	1.85417007565927e-06	3.86957233181066e-05	3.13978456747795e-05	6347/958/3383/3553/5196/6401/6403/7042/7043/7097	10
WP24	Peptide GPCRs	16/641	41/5963	2.06597584976775e-06	4.13195169953551e-05	3.35268010707925e-05	728/1230/2826/1232/1234/1237/10803/3577/3579/10663/1909/2357/2358/4888/6752/7253	16
WP4494	Selective expression of chemokine receptors during T-cell polarization	11/641	24/5963	1.36533667010152e-05	0.000262144640659492	0.000212705081236869	6348/6351/1230/1232/1234/1437/3458/3594/3595/7042/7043	11
WP702	Metapathway biotransformation Phase I and II	30/641	125/5963	1.5016942564333e-05	0.000277235862726148	0.000224950151773409	50515/9435/9469/1545/56603/1594/1555/1562/1557/1558/1559/1565/1576/1551/8529/260293/9420/2326/2327/2328/92292/2938/2939/9027/4837/6783/6822/54657/79799/7364	30
WP43	Oxidation by cytochrome P450	14/641	38/5963	1.97290027031562e-05	0.000350737825833888	0.000284589902540655	1545/56603/1594/1555/1562/1557/1558/1559/1565/1576/1551/8529/260293/9420	14
WP5218	Extrafollicular B cell activation by SARS-CoV-2	19/641	65/5963	3.15544762175388e-05	0.000540933878014952	0.000438915646634939	720/958/941/83416/29851/3433/8519/3458/3586/3569/9636/3687/3689/4094/639/6402/57823/30009/7124	19
WP5090	Complement system in neuronal development and plasticity	23/641	93/5963	9.02770845458849e-05	0.00149424139938016	0.00121243271440934	715/717/720/721/722/725/728/27202/843/1604/629/3426/5199/10584/2219/8547/3458/3687/3689/5648/710/7042/7043	23
WP2876	Pregnane X receptor pathway	11/641	29/5963	0.000114228177635796	0.00182765084217274	0.00148296230614893	5243/1244/1555/1557/1559/1576/1551/2939/27286/6822/54657	11
WP430	Statin inhibition of cholesterol production	10/641	25/5963	0.000139560621872775	0.00209340932809162	0.00169859967410943	64240/64241/335/337/338/341/345/3949/4547/6713	10
WP5092	Interactions of natural killer cells in pancreatic cancer	10/641	25/5963	0.000139560621872775	0.00209340932809162	0.00169859967410943	6347/6348/6351/1437/2214/3002/3458/4277/5551/7124	10
WP2289	Drug induction of bile acid pathway	7/641	13/5963	0.000154091883650142	0.00224133648945662	0.00181862829188366	5243/1244/1576/9971/9970/200931/6822	7
WP4341	Non-genomic actions of 1,25 dihydroxyvitamin D3	18/641	68/5963	0.000208189857384927	0.00288726091284744	0.00234273363542446	6347/958/1594/1673/10964/3458/3569/9636/5600/6300/64127/4939/91543/6258/6772/7097/51311/7124	18
WP2431	Spinal cord injury	23/641	98/5963	0.000211053192197649	0.00288726091284744	0.00234273363542446	301/63827/6347/50515/1282/2919/3627/2920/2212/3383/3458/3552/3553/3569/10288/11025/4321/4318/4843/5320/5743/6403/7124	23
WP1604	Codeine and morphine metabolism	6/641	10/5963	0.000216544568463558	0.00288726091284744	0.00234273363542446	5243/1244/1558/1565/1576/7364	6
WP2911	miRNA targets in ECM and membrane receptors	9/641	22/5963	0.000247747474227325	0.0032140212872734	0.00260786814976131	1278/1281/1282/1284/1290/50509/1291/1293/7058	9
WP545	Complement activation	8/641	18/5963	0.000279658622738071	0.00353252997142827	0.0028663072136589	715/717/720/721/1604/629/5199/5648	8
WP2875	Constitutive androstane receptor pathway	10/641	27/5963	0.000294939081489833	0.003539268977878	0.00287177526713785	5243/1244/1555/1557/1559/1576/2939/9970/6822/54657	10
WP5113	Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway	10/641	27/5963	0.000294939081489833	0.003539268977878	0.00287177526713785	59272/6347/2939/3553/3569/4312/4314/5593/23657/7124	10
WP117	GPCRs, other	12/641	37/5963	0.000314506233207149	0.00368202419364467	0.00298760735010642	27202/1234/3577/3579/1909/29933/11245/53831/59340/53829/5737/6752	12
WP176	Folate metabolism	14/641	48/5963	0.000354098469491875	0.00395272710130465	0.00320725663921649	335/338/875/6347/3383/3458/3553/3569/3949/6288/6289/5054/6648/7124	14
WP558	Complement and coagulation cascades	14/641	48/5963	0.000354098469491875	0.00395272710130465	0.00320725663921649	715/717/721/728/1604/629/3426/5648/5328/5329/5054/710/7056/7450	14
WP2880	Glucocorticoid receptor pathway	17/641	65/5963	0.000362811659221205	0.00395794537332223	0.00321149076344129	51129/8553/330/6347/6364/1907/9982/3589/8972/9970/5142/5743/6286/5272/5552/2040/7056	17
WP4559	Interactions between immune cells and microRNAs in tumor microenvironment	10/641	28/5963	0.000415227905694507	0.00442909766074141	0.00359378538261912	6347/29126/941/1493/3627/3559/8651/7042/7043/51311	10
WP5174	Ulcerative colitis signaling	7/641	15/5963	0.000476210003468787	0.004969147862283	0.00403198401106296	50943/3458/3586/4094/64127/7097/7124	7
WP4329	miRNAs involvement in the immune response in sepsis	12/641	39/5963	0.00054255285777314	0.00542552857773141	0.00440229292491364	6348/6351/3002/3383/3586/3552/3569/3659/3934/407008/51311/7124	12
WP5097	CCL18 signaling pathway	12/641	39/5963	0.00054255285777314	0.00542552857773141	0.00440229292491364	467/1237/1278/1437/3091/440823/4313/4318/6615/6772/7291/652995	12
WP2848	Pluripotent stem cell differentiation pathway	11/641	34/5963	0.000571419097640023	0.00559757483402472	0.00454189186094111	3577/22943/2255/3082/3589/3569/3624/6469/7043/7472/7474	11
WP5094	Orexin receptor pathway	24/641	112/5963	0.00065598705483498	0.00623023259709847	0.00505523258975095	8553/2920/1734/1846/1959/1960/1839/3091/3383/3586/3553/3569/3726/3949/23764/4322/4314/64106/8013/5069/6401/6696/3371/7124	24
WP167	Eicosanoid synthesis	8/641	20/5963	0.000661962213441712	0.00623023259709847	0.00505523258975095	246/240/1800/5320/80339/5730/9536/5743	8
WP4969	RAS and bradykinin pathways in COVID-19	9/641	25/5963	0.000756355866062337	0.00698174645596003	0.00566501357172196	1636/59272/183/1576/3552/3553/5054/710/7124	9
WP299	Nuclear receptors in lipid metabolism and toxicity	9/641	26/5963	0.00104813998916804	0.00931679990371589	0.00755968413240105	5243/1244/64240/1594/1555/1559/1576/9971/9970	9
WP453	Inflammatory response pathway	9/641	26/5963	0.00104813998916804	0.00931679990371589	0.00755968413240105	958/941/1277/1278/1281/3458/3559/3568/3918	9
WP75	Toll-like receptor signaling pathway	19/641	84/5963	0.00118650962376434	0.0103549930801252	0.00840207771852262	6348/6351/958/941/3627/6373/4283/3553/3569/23643/1326/5600/6300/8503/6696/6772/7097/51311/7124	19
WP1433	Nucleotide-binding oligomerization domain (NOD) pathway	11/641	37/5963	0.00126450156186799	0.0108385848160114	0.00879446574983378	84674/834/838/50506/3553/4210/91662/114548/199713/64127/639	11
WP4724	Omega-9 fatty acid synthesis	6/641	13/5963	0.00133149559824696	0.0112125945115534	0.00909793852911129	2180/2182/54898/3992/9415/6319	6
WP5033	Genes associated with the development of rheumatoid arthritis	7/641	18/5963	0.00176424192834155	0.0144918921304645	0.0117587721234033	958/4261/1493/3559/23569/6583/7185	7
WP465	Tryptophan metabolism	10/641	33/5963	0.0017812950743696	0.0144918921304645	0.0117587721234033	8854/316/1545/1562/1576/9420/3620/8942/4129/6999	10
WP697	Estrogen metabolism	6/641	14/5963	0.00212030661628253	0.0169624529302602	0.0137633938249918	1545/1576/2938/412/6783/7364	6
WP716	Vitamin A and carotenoid metabolism	10/641	34/5963	0.00228541006467358	0.0179835546072675	0.0145919193085284	64240/64241/8854/1381/1382/56603/9227/29881/5948/6258	10
WP4522	Metabolic pathway of LDL, HDL and TG, including diseases	6/641	15/5963	0.00321637102482501	0.0249009369663872	0.0202047076262352	335/338/3949/9388/4547/255738	6
WP5044	Kynurenine pathway and links to cell senescence	7/641	20/5963	0.00354801143414808	0.0270324680696997	0.0219342394425195	3620/169355/3458/8564/8942/6999/7124	7
WP3942	PPAR signaling pathway	13/641	54/5963	0.0038764792134014	0.0290735941005105	0.0235904162657651	2180/2182/51129/335/345/126129/2172/9415/4199/4312/4973/6258/6319	13
WP4478	LTF danger signal response pathway	6/641	16/5963	0.00468494622722572	0.0335637938666917	0.0272337801111315	3552/3553/3569/7097/7124/54210	6
WP4493	Cells and molecules involved in local acute inflammatory response 	6/641	16/5963	0.00468494622722572	0.0335637938666917	0.0272337801111315	3383/3552/3569/3689/6403/7124	6
WP516	Hypertrophy model	6/641	16/5963	0.00468494622722572	0.0335637938666917	0.0272337801111315	467/11072/1839/3458/3552/8013	6
WP4538	Regulatory circuits of the STAT3 signaling pathway	16/641	75/5963	0.00523640197167449	0.036962837447114	0.0299917759987548	1271/1439/1441/2151/3595/3601/50615/3559/3568/3575/5600/6300/9180/5159/11122/9021	16
WP2884	NRF2 pathway	22/641	116/5963	0.00542146544177989	0.0377145422036862	0.030601711875798	1244/874/2938/2939/1839/3082/23764/4199/6514/6515/11182/115584/159963/6527/200010/11254/340024/6532/23657/7042/54657/7364	22
WP4304	Oligodendrocyte specification and differentiation, leading to myelin components for CNS	7/641	22/5963	0.00644924988863042	0.0442234278077515	0.0358830444931317	2919/2920/3553/5354/6469/55553/7124	7
WP3967	miR-509-3p alteration of YAP1/ECM axis	6/641	17/5963	0.00659296927326024	0.0445721866361256	0.0361660286301896	1277/1281/1909/6678/7058/7291	6
WP4239	Epithelial to mesenchymal transition in colorectal cancer	24/641	134/5963	0.0079098792581295	0.05273252838753	0.0427873585600572	9076/24146/51208/1282/1284/94234/11211/3091/3678/5600/6300/4313/4318/4854/4855/8503/6615/6678/7042/7043/7291/7480/7472/7474	24
WP3893	Development and heterogeneity of the ILC family	7/641	23/5963	0.00842940526293079	0.0554262263863943	0.0449730345679076	3458/3605/3553/51561/3569/30009/7124	7
WP4723	Omega-3 / omega-6 fatty acid synthesis	5/641	13/5963	0.00871109553112679	0.0565044034451467	0.0458478712164568	2180/2182/54898/3992/9415	5
WP497	Urea cycle and metabolism of amino groups	6/641	18/5963	0.0090073329457196	0.0568884186045448	0.046159462464214	384/445/1373/2628/4942/5009	6
WP5149	Lipid metabolism in senescent cells	6/641	18/5963	0.0090073329457196	0.0568884186045448	0.046159462464214	240/84647/50487/283748/7941/5743	6
WP3614	Photodynamic therapy-induced HIF-1 survival signaling	9/641	35/5963	0.0098100870631586	0.0611537894846251	0.0496203993625247	285/597/664/3091/4843/5743/5054/6515/7043	9
WP3929	Chemokine signaling pathway	26/641	152/5963	0.0106702527356284	0.0656630937577131	0.0532792646718286	6356/6361/6364/6370/10344/6348/6351/1230/2826/1232/1237/10803/3627/6373/2921/6374/4283/3579/10663/2268/2786/3055/4067/5196/8503/6772	26
WP4210	Tryptophan catabolism leading to NAD+ production	5/641	14/5963	0.0123726449282625	0.0742358695695752	0.0602352450454886	3620/8564/8942/10135/6999	5
WP5063	FOXP3 in COVID-19	5/641	14/5963	0.0123726449282625	0.0742358695695752	0.0602352450454886	941/50943/3559/3569/3575	5
WP4496	Signal transduction through IL1R	8/641	31/5963	0.0142866243484095	0.0846614776202042	0.0686946199988499	3552/3553/3557/3569/11213/7042/7043/7124	8
WP4389	Bile acids synthesis and enterohepatic circulation 	4/641	10/5963	0.0163516407068986	0.095716921211114	0.0776650457195443	64240/64241/3949/6555	4
WP2374	Oncostatin M signaling pathway	13/641	64/5963	0.016885690894328	0.0968616107427502	0.0785938508219684	6347/1051/3091/3726/3949/4312/4322/4314/5008/9180/5054/9021/6772	13
WP5109	Familial hyperlipidemia type 2	5/641	15/5963	0.0169507818799813	0.0968616107427502	0.0785938508219684	335/337/338/3949/255738	5
WP4718	Cholesterol metabolism with Bloch and Kandutsch-Russell pathways	10/641	45/5963	0.0188487007815929	0.10643972206076	0.0863655639528096	2180/2182/9023/54898/3992/9415/4597/6319/8435/6713	10
WP727	Monoamine transport	6/641	21/5963	0.0199228110382008	0.111197084864376	0.090225704824165	183/3553/6532/6999/7124/4982	6
WP5122	Prostaglandin and leukotriene metabolism in senescence 	7/641	27/5963	0.020912175438813	0.115377519662417	0.0936177242874872	246/240/3488/5600/5730/9536/5743	7
WP4747	Netrin-UNC5B signaling pathway	10/641	46/5963	0.0218465913109277	0.119163225332333	0.0966894591512348	249/6347/1003/1277/3383/3586/3552/54538/6401/7124	10
WP247	Small ligand GPCRs	5/641	16/5963	0.0225261617221429	0.121489411535153	0.0985769347982599	4543/5724/5737/5739/8698	5
WP4136	Fibrin complement receptor 3 signaling pathway	8/641	35/5963	0.0290866511487683	0.152165175178316	0.123467357052581	6347/3627/2921/3569/3689/23643/4843/7124	8
WP3287	Overview of nanoparticle effects	5/641	17/5963	0.0291649919091773	0.152165175178316	0.123467357052581	1001/1282/3569/5743/7124	5
WP4790	FGF23 signaling in hypophosphatemic rickets and related disorders	5/641	17/5963	0.0291649919091773	0.152165175178316	0.123467357052581	249/1594/5251/142680/6696	5
WP5130	Th17 cell differentiation pathway	12/641	62/5963	0.0302014624945842	0.15587851610108	0.126480374906578	50943/3091/3458/3605/3553/50615/51561/3559/3569/9021/6772/30009	12
WP4197	Immune response to tuberculosis	6/641	23/5963	0.0308151580715339	0.157353998663152	0.127677586634575	3437/8519/3659/8651/6772/6890	6
WP364	IL6 signaling pathway	9/641	42/5963	0.0314773841056332	0.159043624954778	0.129048555336114	183/3055/3569/3659/3726/639/9021/6772/7076	9
WP4495	IL-10 anti-inflammatory signaling pathway 	4/641	12/5963	0.0323889086233399	0.1619445431167	0.131402370511357	3586/3552/3569/6772	4
WP3611	Photodynamic therapy-induced AP-1 survival signaling	10/641	49/5963	0.0329001731169789	0.162804980372679	0.132100532319937	602/2252/1839/3458/3569/3726/5600/6300/4313/7124	10
WP2873	Aryl hydrocarbon receptor pathway	8/641	36/5963	0.0340061328739132	0.166560650811003	0.135147896491384	1545/2939/3458/3553/3726/8140/7124/54657	8
WP236	Adipogenesis	19/641	115/5963	0.0366817945005119	0.17269499728867	0.140125326747386	183/1051/1271/56603/1959/3091/3569/10135/5008/80339/6258/6319/5054/8651/9021/6772/7124/7291/7480	19
WP4721	Eicosanoid metabolism via lipooxygenases (LOX)	6/641	24/5963	0.0374793790956439	0.17269499728867	0.140125326747386	246/240/8529/57105/1800/2358	6
WP5036	Angiotensin II receptor type 1 pathway	6/641	24/5963	0.0374793790956439	0.17269499728867	0.140125326747386	59272/183/1277/1278/3091/3589	6
WP5183	SARS-CoV-2 mitochondrial chronic oxidative stress and endothelial dysfunction	6/641	24/5963	0.0374793790956439	0.17269499728867	0.140125326747386	1636/59272/183/3569/114548/7124	6
WP3932	Focal adhesion: PI3K-Akt-mTOR-signaling pathway	38/641	265/5963	0.0375286194606279	0.17269499728867	0.140125326747386	285/1277/1278/1281/1282/1284/1290/50509/84699/9586/1440/1441/2255/2252/2254/2786/3082/3091/3559/3575/3678/3687/3689/3918/10319/23566/4843/5008/9180/5159/5209/5228/6514/6515/6696/7058/3371/7450	38
WP474	Endochondral ossification	11/641	57/5963	0.0377770306568965	0.17269499728867	0.140125326747386	9507/249/50515/4256/4322/4318/5328/55553/6696/6772/7042	11
WP4808	Endochondral ossification with skeletal dysplasias	11/641	57/5963	0.0377770306568965	0.17269499728867	0.140125326747386	9507/249/50515/4256/4322/4318/5328/55553/6696/6772/7042	11
WP4298	Acute viral myocarditis	14/641	79/5963	0.0402671309107166	0.182341724878717	0.147952715362117	834/1232/1234/1604/941/3458/3586/3569/3689/4318/64127/8651/6772/7124	14
WP5108	Familial  hyperlipidemia type 1	4/641	13/5963	0.0429123811087681	0.190721693816747	0.154752251561834	51129/335/337/3949	4
WP554	ACE inhibitor pathway	4/641	13/5963	0.0429123811087681	0.190721693816747	0.154752251561834	1636/59272/183/1215	4
WP2895	Differentiation of white and brown adipocyte	5/641	19/5963	0.0458196197772469	0.199940159027987	0.162232146579726	1051/253738/3224/27129/51316	5
WP5066	FOXA2 pathway	5/641	19/5963	0.0458196197772469	0.199940159027987	0.162232146579726	1244/338/2938/2939/4547	5
WP3937	Microglia pathogen phagocytosis pathway	8/641	39/5963	0.0520485428479996	0.225074779883242	0.182626466133332	2207/2209/3055/3689/4067/4688/8503/54210	8
WP2849	Hematopoietic stem cell differentiation	9/641	46/5963	0.0530198323967527	0.226788272101063	0.184016799731125	4261/1437/1440/3552/3553/3569/4778/6688/23650	9
WP4719	Eicosanoid metabolism via cyclooxygenases (COX)	6/641	26/5963	0.0533897390571252	0.226788272101063	0.184016799731125	8529/5730/9536/5737/5739/5743	6
WP12	Osteoclast signaling	4/641	14/5963	0.0551282755809704	0.228117002404015	0.185094936161153	1513/8111/6696/4982	4
WP2879	Farnesoid X receptor pathway	4/641	14/5963	0.0551282755809704	0.228117002404015	0.185094936161153	1576/8431/9971/6822	4
WP3971	OSX and miRNAs in tooth development	4/641	14/5963	0.0551282755809704	0.228117002404015	0.185094936161153	249/22943/4854/4855	4
WP98	Prostaglandin synthesis and regulation	8/641	41/5963	0.066962263127081	0.274716976931614	0.222906319001529	301/1909/3290/5730/9536/5737/5739/5743	8
WP3	Transcriptional activation by NRF2 in response to phytochemicals	4/641	15/5963	0.0690110005631481	0.278363699750513	0.225865282692302	1051/2939/4094/23657	4
WP4842	Mammalian disorder of sexual development	4/641	15/5963	0.0690110005631481	0.278363699750513	0.225865282692302	84733/2254/5600/5730	4
WP5087	Malignant pleural mesothelioma	50/641	381/5963	0.0747786188641125	0.29911447545645	0.242702534909839	72/285/467/834/6347/6351/29126/1001/1003/1282/1284/1437/1440/115908/1496/2919/3627/6374/22943/2255/2252/2254/8061/11211/1839/3082/3091/3620/3586/3553/3569/3689/3918/10319/4313/4314/4318/114548/5159/5228/5328/6401/6423/6425/8140/6678/6772/7480/7472/7474	50
WP4595	Urea cycle and associated pathways	5/641	22/5963	0.0795257481657256	0.315474042310316	0.255976744857055	445/1373/4843/4942/5009	5
WP2815	Mammary gland development pathway - Involution (Stage 4 of 4)	3/641	10/5963	0.0835194049927675	0.326400264018223	0.26484231948847	1116/4318/9021	3
WP2840	Hair follicle development: cytodifferentiation - part 3 of 3	11/641	65/5963	0.0843443351691618	0.326400264018223	0.26484231948847	22943/1959/94234/2619/3458/3488/5653/5650/4488/22822/7474	11
WP3413	NOTCH1 regulation of endothelial cell calcification	4/641	16/5963	0.0845059468434832	0.326400264018223	0.26484231948847	249/2702/4256/55553	4
WP4877	Host-pathogen interaction of human coronaviruses - MAPK signaling	7/641	36/5963	0.0850000687547456	0.326400264018223	0.26484231948847	684/8519/10581/10410/3726/5600/6300	7
WP706	Sudden infant death syndrome (SIDS) susceptibility pathways	19/641	128/5963	0.0897263574296388	0.341814694970053	0.277349642848508	116/8553/720/721/1051/2328/3091/3586/3552/3553/3557/3569/3764/5354/6507/6532/6752/7124/11076	19
WP3668	Hypothesized pathways in pathogenesis of cardiovascular disease	5/641	23/5963	0.0930564676363344	0.351709483979847	0.285378309369612	285/2022/2200/4053/5054	5
WP5144	NRP1-triggered signaling pathways in pancreatic cancer 	9/641	52/5963	0.100220896067897	0.375828360254614	0.304948450206595	1003/1277/1278/3082/4313/4318/6615/7042/7043	9
WP5111	Familial hyperlipidemia type 4	4/641	17/5963	0.101533932977116	0.377800680845082	0.306548798054124	335/337/3949/4547	4
WP3871	Valproic acid pathway	3/641	11/5963	0.106007856226141	0.385483113549603	0.312782350906476	116285/1555/1559	3
WP4583	Biomarkers for urea cycle disorders	3/641	11/5963	0.106007856226141	0.385483113549603	0.312782350906476	445/2628/5009	3
WP4707	Aspirin and miRNAs	3/641	11/5963	0.106007856226141	0.385483113549603	0.312782350906476	283120/4597/5743	3
WP5083	Neuroinflammation and glutamatergic signaling	17/641	115/5963	0.107315353649015	0.387303531966371	0.314259444797275	2893/2898/2906/116443/3458/3586/3552/3553/3569/29968/6507/6515/9021/6772/7042/7043/7124	17
WP3927	BMP signaling in eyelid development	4/641	18/5963	0.119995645923619	0.429835149577144	0.348769748560402	2255/2296/3625/6469	4
WP4545	Oxysterols derived from cholesterol	6/641	32/5963	0.122219442150141	0.434558016533835	0.352601899380524	134526/9023/1576/9420/3605/3638	6
WP3892	Development of pulmonary dendritic cells and macrophage subsets	3/641	12/5963	0.130547505427074	0.450811529532343	0.365790056857384	55509/1437/6688	3
WP5110	Familial hyperlipidemia type 3	3/641	12/5963	0.130547505427074	0.450811529532343	0.365790056857384	335/337/3949	3
WP5112	Familial hyperlipidemia type 5	3/641	12/5963	0.130547505427074	0.450811529532343	0.365790056857384	335/337/3949	3
WP5188	Retinol Metabolism	3/641	12/5963	0.130547505427074	0.450811529532343	0.365790056857384	316/1551/9227	3
WP4756	Renin-angiotensin-aldosterone system (RAAS)	6/641	33/5963	0.136623377489971	0.468423008537045	0.380080072716462	1636/183/1215/84699/9586/3283	6
WP3646	Hepatitis C and hepatocellular carcinoma	8/641	48/5963	0.137802931811927	0.46911636361507	0.380642663459596	330/1284/3577/3091/3569/4312/4843/5743	8
WP3599	Transcription factor regulation in adipogenesis	4/641	19/5963	0.139775919562652	0.469967548441112	0.381333317814061	1051/3569/7124/7291	4
WP4767	FGFR3 signaling in chondrocyte proliferation and terminal differentiation	5/641	26/5963	0.140011165473081	0.469967548441112	0.381333317814061	2254/5600/6300/6615/6772	5
WP4879	Overlap between signal transduction pathways contributing to LMNA laminopathies	8/641	49/5963	0.150189759975734	0.500632533252448	0.406214994086416	1051/1513/3726/4129/6696/7042/4982/7480	8
WP4008	NO/cGMP/PKG mediated neuroprotection	6/641	34/5963	0.151781602264756	0.502449441979883	0.407689240202975	2906/3458/3553/4843/5593/7124	6
WP4655	Cytosolic DNA-sensing pathway	9/641	57/5963	0.153383896360719	0.504275823651679	0.409171172699827	834/843/6351/9560/3627/3553/3569/9636/81030	9
WP1434	Osteopontin signaling	3/641	13/5963	0.156838042722566	0.507669005935255	0.411924412710623	4318/5328/6696	3
WP5178	Disorders of fructose metabolism	3/641	13/5963	0.156838042722566	0.507669005935255	0.411924412710623	229/3795/6514	3
WP3869	Cannabinoid receptor signaling	5/641	27/5963	0.157588920592402	0.507669005935255	0.411924412710623	1557/1559/1576/5600/6300	5
WP4917	Proximal tubule transport	7/641	42/5963	0.158879227913905	0.508413529324495	0.412528521601016	5243/1244/6514/142680/6519/340024/11136	7
WP3645	NAD+ biosynthetic pathways	4/641	20/5963	0.160747743374948	0.510986204105794	0.414615998945491	952/3620/10135/6999	4
WP4787	Osteoblast differentiation and related diseases	14/641	98/5963	0.163682680854939	0.516892676384018	0.419408531276506	2255/2252/2254/11211/5600/6300/4854/4855/5288/8503/6772/7480/7472/7474	14
WP4786	Type I collagen synthesis in the context of osteogenesis imperfecta	5/641	28/5963	0.176012809886721	0.55029188608642	0.446508767219244	9509/1277/1278/60681/4982	5
WP4963	p53 transcriptional gene network	9/641	59/5963	0.177892389675022	0.55029188608642	0.446508767219244	6347/126129/55332/3383/9636/4688/5268/5054/23657	9
WP262	Ebstein-Barr virus LMP1 signaling	4/641	21/5963	0.182775932177996	0.55029188608642	0.446508767219244	6364/9260/7124/7185	4
WP4141	PI3K/AKT/mTOR - vitamin D3 signaling	4/641	21/5963	0.182775932177996	0.55029188608642	0.446508767219244	941/3101/3586/6515	4
WP4564	Neural crest cell migration during development	6/641	36/5963	0.184179927984181	0.55029188608642	0.446508767219244	2047/2151/4313/4318/8503/7291	6
WP3935	Leptin-insulin signaling overlap	3/641	14/5963	0.18457707012482	0.55029188608642	0.446508767219244	8503/8651/9021	3
WP4337	ncRNAs involved in STAT3 signaling in hepatocellular carcinoma	3/641	14/5963	0.18457707012482	0.55029188608642	0.446508767219244	3589/3569/652995	3
WP4582	Cancer immunotherapy by CTLA4 blockade	3/641	14/5963	0.18457707012482	0.55029188608642	0.446508767219244	941/1493/8503	3
WP5061	Fatty acid transporters	3/641	14/5963	0.18457707012482	0.55029188608642	0.446508767219244	2180/2182/2172	3
WP4331	Neovascularisation processes	6/641	37/5963	0.201319420248956	0.596501985922832	0.48400380436721	3091/4318/4854/4855/7042/7043	6
WP2203	Thymic stromal lymphopoietin (TSLP) signaling pathway	7/641	45/5963	0.204011225382545	0.598459396404529	0.485592054100166	6356/3055/3559/3569/3575/4067/6772	7
WP5053	Development of ureteric collection system	8/641	53/5963	0.204669675416443	0.598459396404529	0.485592054100166	2296/80144/158326/341640/2674/80000/6469/7042	8
WP3591	Sleep regulation	4/641	22/5963	0.205720417514057	0.598459396404529	0.485592054100166	100/134/3569/5730	4
WP4258	lncRNA in canonical Wnt signaling and colorectal cancer	11/641	78/5963	0.212504311482736	0.609910250043536	0.494883316921291	467/22943/8061/11211/283120/5328/6423/6425/7480/7472/7474	11
WP272	Blood clotting cascade	3/641	15/5963	0.213468587515238	0.609910250043536	0.494883316921291	5328/5054/7450	3
WP698	Glucuronidation	3/641	15/5963	0.213468587515238	0.609910250043536	0.494883316921291	54657/79799/7364	3
WP4816	TGF-beta receptor signaling in skeletal dysplasias	8/641	54/5963	0.219390122009325	0.62311987316258	0.505601651469637	2022/2200/3458/3624/5054/6696/6772/7124	8
WP4357	NRF2-ARE regulation	4/641	23/5963	0.229439143804104	0.644039701906256	0.522576073915164	1051/2939/4094/23657	4
WP4585	Cancer immunotherapy by PD-1 blockade	4/641	23/5963	0.229439143804104	0.644039701906256	0.522576073915164	10538/29126/3458/80380	4
WP4241	Type 2 papillary renal cell carcinoma	5/641	31/5963	0.235554887979268	0.654357715602688	0.530948146432006	1513/112399/3091/7042/7043	5
WP4565	Neural crest cell migration in cancer	6/641	39/5963	0.237204671905975	0.654357715602688	0.530948146432006	2047/2151/4313/4318/8503/7291	6
WP534	Glycolysis and gluconeogenesis	6/641	39/5963	0.237204671905975	0.654357715602688	0.530948146432006	229/3099/3101/5313/6514/6515	6
WP3644	NAD+ metabolism	3/641	16/5963	0.243229196901027	0.66335235518462	0.538246428548924	952/10135/203447	3
WP4225	Pyrimidine metabolism and related diseases	3/641	16/5963	0.243229196901027	0.66335235518462	0.538246428548924	1373/5009/1890	3
WP3941	Oxidative damage response	6/641	40/5963	0.255834420481065	0.691801168997343	0.561329895896967	715/717/721/728/7124/7185	6
WP3298	Melatonin metabolism and effects	5/641	32/5963	0.256542933503181	0.691801168997343	0.561329895896967	1545/1557/1565/406938/4543	5
WP2324	AGE/RAGE pathway	9/641	65/5963	0.260564938896072	0.698721623855389	0.566945177251084	249/3091/3625/4322/4313/4316/4318/4843/6772	9
WP4830	GDNF/RET signaling axis	3/641	17/5963	0.273592467741866	0.729579913978308	0.591983702131522	2296/2674/26585	3
WP4900	Purinergic signaling	4/641	25/5963	0.278635782497289	0.738923622092258	0.599565219680122	134/5027/53829/5031	4
WP560	TGF-beta receptor signaling	7/641	50/5963	0.288059153033664	0.759716447561313	0.616436591222995	2022/3458/3624/5054/6696/6772/7124	7
WP4846	SARS-CoV-2 and COVID-19 pathway	2/641	10/5963	0.29302449136565	0.76740063601377	0.622671568695383	59272/340024	2
WP2036	TNF-related weak inducer of apoptosis (TWEAK) signaling pathway	6/641	42/5963	0.294170243805278	0.76740063601377	0.622671568695383	330/6347/3569/4318/7124/7185	6
WP3863	T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection	8/641	59/5963	0.298041549309703	0.773296992803553	0.627455893283585	1437/1493/29851/3458/3586/3937/1326/7124	8
WP3877	MYD88 distinct input-output pathway	3/641	18/5963	0.304311832105515	0.785320857046489	0.6372120989193	3552/7097/51311	3
WP4172	PI3K-Akt signaling pathway	33/641	280/5963	0.311169304030405	0.798723347243821	0.648086926491697	285/1277/1278/1282/1284/1291/1293/84699/9586/1440/1441/2255/2252/2254/2786/3082/3559/3569/3575/3678/3918/10319/23566/5008/9180/5159/5228/8503/6696/7058/7097/3371/7450	33
WP2371	Parkinson's disease pathway	5/641	35/5963	0.321721808236321	0.820805671119921	0.666004601566603	120892/5600/6300/9627/9246	5
WP2197	Endothelin pathways	4/641	27/5963	0.329275273576823	0.820805671119921	0.666004601566603	1909/2769/4852/5739	4
WP229	Irinotecan pathway	2/641	11/5963	0.334583743618874	0.820805671119921	0.666004601566603	1244/1576	2
WP3630	NAD metabolism, sirtuins and aging	2/641	11/5963	0.334583743618874	0.820805671119921	0.666004601566603	3091/10135	2
WP3930	EDA signaling in hair follicle development	2/641	11/5963	0.334583743618874	0.820805671119921	0.666004601566603	22943/6469	2
WP4271	Vitamin B12 disorders	2/641	11/5963	0.334583743618874	0.820805671119921	0.666004601566603	8029/6947	2
WP5052	Nephrogenesis	2/641	11/5963	0.334583743618874	0.820805671119921	0.666004601566603	8854/80000	2
WP4961	STING pathway in Kawasaki-like disease and COVID-19	3/641	19/5963	0.335162315707301	0.820805671119921	0.666004601566603	2212/3553/114548	3
WP5181	Roles of ceramides in the development of insulin resistance	3/641	19/5963	0.335162315707301	0.820805671119921	0.666004601566603	2180/7124/7185	3
WP3865	Novel intracellular components of RIG-I-like receptor (RLR) pathway	7/641	53/5963	0.341890242236527	0.833032062302198	0.67592513827152	843/3627/3458/9636/5600/6300/7124	7
WP2870	Extracellular vesicle-mediated signaling in recipient cells	4/641	28/5963	0.354819017525174	0.860167315212543	0.697942777694388	3082/7042/7043/7474	4
WP2018	RANKL/RANK signaling pathway	7/641	54/5963	0.360134940993769	0.8621419894903	0.699545035332042	1513/3383/4067/6688/6772/4982/7185	7
WP3640	Imatinib and chronic myeloid leukemia	3/641	20/5963	0.365941357883599	0.8621419894903	0.699545035332042	5243/5159/11040	3
WP4224	Purine metabolism and related disorders	3/641	20/5963	0.365941357883599	0.8621419894903	0.699545035332042	100/316/7498	3
WP4300	Extracellular vesicles in the crosstalk of cardiac cells	3/641	20/5963	0.365941357883599	0.8621419894903	0.699545035332042	3569/4318/6696	3
WP4336	ncRNAs involved in Wnt signaling in hepatocellular carcinoma	9/641	72/5963	0.368572322244473	0.8621419894903	0.699545035332042	22943/8061/11211/5328/6423/6425/7480/7472/7474	9
WP5098	T-cell activation SARS-CoV-2	10/641	81/5963	0.371300534288009	0.8621419894903	0.699545035332042	941/1493/29851/3458/3594/3595/3605/51561/3937/7124	10
WP2814	Mammary gland development pathway - Puberty (Stage 2 of 4)	2/641	12/5963	0.375390991257235	0.8621419894903	0.699545035332042	8061/7076	2
WP2881	Estrogen receptor pathway	2/641	12/5963	0.375390991257235	0.8621419894903	0.699545035332042	1545/8431	2
WP4211	Transcriptional cascade regulating adipogenesis	2/641	12/5963	0.375390991257235	0.8621419894903	0.699545035332042	1051/1959	2
WP4792	Purine metabolism	2/641	12/5963	0.375390991257235	0.8621419894903	0.699545035332042	100/7498	2
WP5171	Metabolic pathway leukotriene 	2/641	12/5963	0.375390991257235	0.8621419894903	0.699545035332042	240/1800	2
WP4864	Host-pathogen interaction of human coronaviruses - apoptosis	3/641	21/5963	0.396468928834533	0.905733580343586	0.734915405103349	5600/6300/7124	3
WP4018	Clear cell renal cell carcinoma pathways	10/641	83/5963	0.401414210304821	0.905733580343586	0.734915405103349	229/3091/3099/3101/4199/5159/5313/29968/7042/7043	10
WP2839	Hair follicle development: organogenesis - part 2 of 3	4/641	30/5963	0.405784762050871	0.905733580343586	0.734915405103349	3624/6469/6615/7474	4
WP4868	Type I interferon induction and signaling during SARS-CoV-2 infection	4/641	30/5963	0.405784762050871	0.905733580343586	0.734915405103349	59272/4939/6772/7097	4
WP306	Focal adhesion	21/641	183/5963	0.40933362517834	0.905733580343586	0.734915405103349	330/1277/1278/1282/1284/1290/50509/2268/2318/3055/3082/3678/3918/10319/5159/5228/8503/6696/7058/3371/7450	21
WP2828	Bladder cancer	5/641	39/5963	0.410730820583389	0.905733580343586	0.734915405103349	1839/4312/4313/4318/1890	5
WP2435	Quercetin and Nf-kB / AP-1 induced apoptosis	2/641	13/5963	0.41512789099081	0.905733580343586	0.734915405103349	4312/5743	2
WP2813	Mammary gland development pathway - Embryonic development (Stage 1 of 4)	2/641	13/5963	0.41512789099081	0.905733580343586	0.734915405103349	249/7124	2
WP5176	Disorders of bile acid synthesis and biliary transport	2/641	13/5963	0.41512789099081	0.905733580343586	0.734915405103349	1244/9420	2
WP5192	Modulation of the PI3K-Akt-mTOR signaling by bioactive sphingolipids	2/641	13/5963	0.41512789099081	0.905733580343586	0.734915405103349	56624/3091	2
WP692	Sulfation biotransformation reaction	2/641	13/5963	0.41512789099081	0.905733580343586	0.734915405103349	6783/6822	2
WP357	Fatty acid biosynthesis	3/641	22/5963	0.426587114832502	0.922350518556761	0.748398447074565	2180/2182/6319	3
WP3612	Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling	3/641	22/5963	0.426587114832502	0.922350518556761	0.748398447074565	1244/5600/6300	3
WP2406	Cardiac progenitor differentiation	4/641	31/5963	0.431004002654071	0.927721620062575	0.752756577682352	290/22943/3624/7070	4
WP69	T-cell receptor signaling pathway	10/641	86/5963	0.446672813172179	0.956141786173126	0.775816800184335	1234/29851/3601/3605/3552/3553/3569/3937/1326/3604	10
WP3925	Amino acid metabolism	9/641	77/5963	0.448355533612283	0.956141786173126	0.775816800184335	384/445/586/875/1373/3034/4942/5009/6999	9
WP58	Monoamine GPCRs	2/641	14/5963	0.453553027801809	0.956141786173126	0.775816800184335	3274/3352	2
WP3845	Canonical and non-canonical Notch signaling	3/641	23/5963	0.456159310486762	0.956141786173126	0.775816800184335	4237/4854/4855	3
WP4483	Relationship between inflammation, COX-2 and EGFR	3/641	23/5963	0.456159310486762	0.956141786173126	0.775816800184335	4312/51365/5743	3
WP5046	NAD metabolism in oncogene-induced senescence and mitochondrial dysfunction-associated senescence	3/641	23/5963	0.456159310486762	0.956141786173126	0.775816800184335	3553/3569/10135	3
WP4666	Hepatitis B infection	15/641	134/5963	0.475110772738666	0.991535525715477	0.804535404637558	843/84699/9586/1959/1960/3569/5600/6300/4318/8503/6772/7042/7043/7097/7124	15
WP3945	TYROBP causal network in microglia	7/641	61/5963	0.487805266445847	0.993220895244432	0.80590291938693	10261/3687/3689/4094/4688/5341/6696	7
WP197	Cholesterol biosynthesis pathway	2/641	15/5963	0.490489095538205	0.993220895244432	0.80590291938693	4597/6713	2
WP2855	Dopaminergic neurogenesis	2/641	15/5963	0.490489095538205	0.993220895244432	0.80590291938693	4929/6469	2
WP4159	GABA receptor signaling	2/641	15/5963	0.490489095538205	0.993220895244432	0.80590291938693	2557/2562	2
WP4872	MAP3K1 role in promoting and blocking gonadal determination	2/641	15/5963	0.490489095538205	0.993220895244432	0.80590291938693	2254/5600	2
WP5182	Pro-survival signaling of neuroprotectin D1	2/641	15/5963	0.490489095538205	0.993220895244432	0.80590291938693	330/7124	2
WP2864	Apoptosis-related network due to altered Notch3 in ovarian cancer	6/641	52/5963	0.492472027225364	0.993220895244432	0.80590291938693	602/79092/3575/9021/7124/7185	6
WP395	IL-4 signaling pathway	6/641	52/5963	0.492472027225364	0.993220895244432	0.80590291938693	1051/9046/5600/8651/9021/6772	6
WP4746	Thyroid hormones production and peripheral downstream signaling effects	9/641	80/5963	0.495691610547008	0.9955312680442	0.807777563983233	1734/50506/405753/4852/5593/6469/5172/7038/7253	9
WP5205	CLOCKED CONTROLLED AUTOPHAGY IN BONE METABOLISM	8/641	71/5963	0.500332828103876	0.999999278479011	0.811402923327268	8553/115908/1513/22943/3569/4982/7480/7474	8
WP1591	Heart development	4/641	34/5963	0.504576319591936	0.999999278479011	0.811402923327268	8553/2255/2296/6469	4
WP205	IL-7 signaling pathway	3/641	25/5963	0.513219132708102	0.999999278479011	0.811402923327268	3559/3575/6772	3
WP3613	Photodynamic therapy-induced unfolded protein response	3/641	25/5963	0.513219132708102	0.999999278479011	0.811402923327268	467/121506/6783	3
WP4950	16p11.2 distal deletion syndrome	3/641	25/5963	0.513219132708102	0.999999278479011	0.811402923327268	8519/5350/7185	3
WP4673	Male infertility	11/641	100/5963	0.515815816101473	0.999999278479011	0.811402923327268	5243/338/56603/2346/4313/4318/4843/29968/6648/7124/10537	11
WP2267	Synaptic vesicle pathway	5/641	44/5963	0.519003448181305	0.999999278479011	0.811402923327268	22999/246213/6507/6581/6532	5
WP2011	SREBF and miR33 in cholesterol and lipid homeostasis	2/641	16/5963	0.525811938200658	0.999999278479011	0.811402923327268	3949/6319	2
WP368	Mitochondrial long chain fatty acid beta-oxidation	2/641	16/5963	0.525811938200658	0.999999278479011	0.811402923327268	2180/2182	2
WP4558	Overview of interferons-mediated signaling pathway	2/641	16/5963	0.525811938200658	0.999999278479011	0.811402923327268	3458/6772	2
WP4884	Pathogenesis of SARS-CoV-2 mediated by nsp9-nsp10 complex	2/641	16/5963	0.525811938200658	0.999999278479011	0.811402923327268	3569/64386	2
WP2858	Ectoderm differentiation	13/641	120/5963	0.532459606948422	0.999999278479011	0.811402923327268	398/6347/1496/54898/57476/9687/152789/3801/3853/4061/6469/6781/4982	13
WP3851	TLR4 signaling and tolerance	3/641	26/5963	0.540529420671785	0.999999278479011	0.811402923327268	3569/11213/7124	3
WP4829	mBDNF and proBDNF regulation of GABA neurotransmission	3/641	26/5963	0.540529420671785	0.999999278479011	0.811402923327268	2557/2562/8503	3
WP3594	Circadian rhythm genes	17/641	159/5963	0.54844128630557	0.999999278479011	0.811402923327268	100/134/56938/8553/1960/50865/3569/4543/4547/10135/4843/5551/5593/60675/5730/5054/6532	17
WP4658	Small cell lung cancer	10/641	93/5963	0.549793334814338	0.999999278479011	0.811402923327268	330/1282/1284/3918/10319/4843/8503/5743/6258/7185	10
WP254	Apoptosis	9/641	84/5963	0.556912795068443	0.999999278479011	0.811402923327268	330/834/843/3002/8739/3659/5551/7124/7185	9
WP3303	RAC1/PAK1/p38/MMP2 pathway	7/641	65/5963	0.557589232471691	0.999999278479011	0.811402923327268	285/9046/5600/6300/4313/4843/79931	7
WP100	Glutathione metabolism	2/641	17/5963	0.559441200928498	0.999999278479011	0.811402923327268	290/2938	2
WP3678	Amplification and expansion of oncogenic pathways as metastatic traits	2/641	17/5963	0.559441200928498	0.999999278479011	0.811402923327268	3371/7472	2
WP3874	Canonical and non-canonical TGF-B signaling	2/641	17/5963	0.559441200928498	0.999999278479011	0.811402923327268	26585/4017	2
WP4784	Proteoglycan biosynthesis	2/641	17/5963	0.559441200928498	0.999999278479011	0.811402923327268	9469/55790	2
WP4912	SARS coronavirus and innate immunity	2/641	17/5963	0.559441200928498	0.999999278479011	0.811402923327268	59272/6772	2
WP5074	Kallmann syndrome	2/641	17/5963	0.559441200928498	0.999999278479011	0.811402923327268	60675/9723	2
WP2643	Nanoparticle-mediated activation of receptor signaling	3/641	27/5963	0.566936189058655	0.999999278479011	0.811402923327268	1277/5600/6300	3
WP286	IL-3 signaling pathway	5/641	47/5963	0.579778661909815	0.999999278479011	0.811402923327268	1232/1439/3055/3568/4067	5
WP3859	TGF-beta signaling in thyroid cells for epithelial-mesenchymal transition	2/641	18/5963	0.59133237203137	0.999999278479011	0.811402923327268	6615/3371	2
WP4760	PKC-gamma calcium signaling pathway in ataxia	2/641	18/5963	0.59133237203137	0.999999278479011	0.811402923327268	2769/2893	2
WP5193	Cholesterol synthesis disorders	2/641	18/5963	0.59133237203137	0.999999278479011	0.811402923327268	4597/6713	2
WP4150	Wnt signaling in kidney disease	3/641	28/5963	0.592390249642672	0.999999278479011	0.811402923327268	7480/7472/7474	3
WP4561	Cell migration and invasion through p75NTR	3/641	28/5963	0.592390249642672	0.999999278479011	0.811402923327268	4313/4318/7291	3
WP399	Wnt signaling pathway and pluripotency	9/641	87/5963	0.600757294505928	0.999999278479011	0.811402923327268	8061/11211/3949/120892/4316/5328/7480/7472/7474	9
WP127	IL-5 signaling pathway	4/641	39/5963	0.616518278355573	0.999999278479011	0.811402923327268	1439/3568/4067/6772	4
WP408	Oxidative stress response	3/641	29/5963	0.616855575607154	0.999999278479011	0.811402923327268	3726/6648/7498	3
WP4698	Vitamin D-sensitive calcium signaling in depression	3/641	29/5963	0.616855575607154	0.999999278479011	0.811402923327268	775/1594/2906	3
WP1584	Type II diabetes mellitus	2/641	19/5963	0.621470025716555	0.999999278479011	0.811402923327268	6514/7124	2
WP325	Triacylglyceride synthesis	2/641	19/5963	0.621470025716555	0.999999278479011	0.811402923327268	56895/2819	2
WP4722	Glycerolipids and glycerophospholipids	2/641	19/5963	0.621470025716555	0.999999278479011	0.811402923327268	56895/80339	2
WP4149	White fat cell differentiation	3/641	30/5963	0.640307888224519	0.999999278479011	0.811402923327268	1051/1959/7480	3
WP4657	22q11.2 copy number variation syndrome	9/641	90/5963	0.642384428128894	0.999999278479011	0.811402923327268	8854/9076/56603/2255/2296/4942/5625/6469/7450	9
WP2878	PPAR-alpha pathway	2/641	20/5963	0.649862099920217	0.999999278479011	0.811402923327268	335/345	2
WP3580	Methionine de novo and salvage pathway	2/641	20/5963	0.649862099920217	0.999999278479011	0.811402923327268	51074/259307	2
WP4313	Ferroptosis	6/641	61/5963	0.653134506112407	0.999999278479011	0.811402923327268	2180/2182/246/875/1803/23657	6
WP2332	Interleukin-11 signaling pathway	4/641	41/5963	0.656613456246661	0.999999278479011	0.811402923327268	3383/3589/9021/6772	4
WP4844	Influence of laminopathies on Wnt signaling	3/641	31/5963	0.662733304535638	0.999999278479011	0.811402923327268	1051/6696/7480	3
WP2359	Parkin-ubiquitin proteasomal system pathway	6/641	62/5963	0.668942508944203	0.999999278479011	0.811402923327268	834/3310/9627/10381/84617/9246	6
WP382	MAPK signaling pathway	21/641	210/5963	0.673089932514819	0.999999278479011	0.811402923327268	775/994/1846/2255/2252/2254/2318/3310/3552/3553/120892/1326/5600/6300/22808/5159/283748/115727/7042/7043/7124	21
WP1423	Ganglio sphingolipid metabolism	1/641	10/5963	0.679590473652282	0.999999278479011	0.811402923327268	6482	1
WP2333	Trans-sulfuration pathway	1/641	10/5963	0.679590473652282	0.999999278479011	0.811402923327268	875	1
WP2436	Dopamine metabolism	1/641	10/5963	0.679590473652282	0.999999278479011	0.811402923327268	4129	1
WP3656	Interleukin-1 induced activation of NF-kB	1/641	10/5963	0.679590473652282	0.999999278479011	0.811402923327268	3552	1
WP5050	TCA cycle in senescence	1/641	10/5963	0.679590473652282	0.999999278479011	0.811402923327268	4199	1
WP5104	Acquired partial lipodystrophy / Barraquer-Simons syndrome	1/641	10/5963	0.679590473652282	0.999999278479011	0.811402923327268	629	1
WP5187	mRNA vaccine activation of dendritic cell and induction of IFN-1	1/641	10/5963	0.679590473652282	0.999999278479011	0.811402923327268	51311	1
WP4823	Genes controlling nephrogenesis	3/641	32/5963	0.684127058880762	0.999999278479011	0.811402923327268	2296/5159/6469	3
WP2586	Aryl hydrocarbon receptor pathway	4/641	43/5963	0.693791199354518	0.999999278479011	0.811402923327268	1545/135112/5743/7124	4
WP4539	Synaptic signaling pathways associated with autism spectrum disorder	4/641	43/5963	0.693791199354518	0.999999278479011	0.811402923327268	775/2906/116443/8503	4
WP4482	Vitamin D in inflammatory diseases	2/641	22/5963	0.701529860344173	0.999999278479011	0.811402923327268	3569/7124	2
WP410	Exercise-induced circadian regulation	4/641	44/5963	0.711269974471839	0.999999278479011	0.811402923327268	1051/50486/2674/10381	4
WP3679	Cell-type dependent selectivity of CCK2R signaling	1/641	11/5963	0.714091146655622	0.999999278479011	0.811402923327268	952	1
WP4788	Autosomal recessive osteopetrosis pathways	1/641	11/5963	0.714091146655622	0.999999278479011	0.811402923327268	29887	1
WP4919	Neuroinflammation	1/641	11/5963	0.714091146655622	0.999999278479011	0.811402923327268	4843	1
WP4947	Nitric oxide metabolism in cystic fibrosis	1/641	11/5963	0.714091146655622	0.999999278479011	0.811402923327268	4843	1
WP5191	ResolvinE1 and ResolvinD1 signaling pathways promoting inflammation resolution	1/641	11/5963	0.714091146655622	0.999999278479011	0.811402923327268	2358	1
WP170	Nuclear receptors	3/641	34/5963	0.723839015077313	0.999999278479011	0.811402923327268	9970/4929/6258	3
WP2361	Gastric cancer network 1	2/641	23/5963	0.724898484140117	0.999999278479011	0.811402923327268	11082/6286	2
WP34	Ovarian infertility	2/641	23/5963	0.724898484140117	0.999999278479011	0.811402923327268	1051/2701	2
WP5064	7-oxo-C and 7-beta-HC pathways	2/641	23/5963	0.724898484140117	0.999999278479011	0.811402923327268	134526/3290	2
WP428	Wnt signaling	9/641	98/5963	0.74061344052652	0.999999278479011	0.811402923327268	22943/8061/11211/5328/6423/6425/7480/7472/7474	9
WP3527	Pre-implantation embryo	3/641	35/5963	0.742182943044926	0.999999278479011	0.811402923327268	366/55509/94234	3
WP2513	Nanoparticle triggered regulated necrosis	1/641	12/5963	0.744882069873658	0.999999278479011	0.811402923327268	7124	1
WP3876	BMP2-WNT4-FOXO1 pathway in primary endometrial stromal cell differentiation	1/641	12/5963	0.744882069873658	0.999999278479011	0.811402923327268	22943	1
WP4190	Mevalonate arm of cholesterol biosynthesis pathway	1/641	12/5963	0.744882069873658	0.999999278479011	0.811402923327268	4597	1
WP4504	Cysteine and methionine catabolism	1/641	12/5963	0.744882069873658	0.999999278479011	0.811402923327268	875	1
WP5173	Disorders of galactose metabolism 	1/641	12/5963	0.744882069873658	0.999999278479011	0.811402923327268	6514	1
WP1539	Angiogenesis	2/641	24/5963	0.746701152636236	0.999999278479011	0.811402923327268	3091/4318	2
WP26	S1P receptor signal transduction	2/641	24/5963	0.746701152636236	0.999999278479011	0.811402923327268	6300/8877	2
WP289	Myometrial relaxation and contraction pathways	12/641	131/5963	0.764189290241103	0.999999278479011	0.811402923327268	133/467/2786/3488/3553/3569/23764/5142/10268/6004/5999/8490	12
WP1528	Physiological and pathological hypertrophy of the heart	2/641	25/5963	0.767003936977813	0.999999278479011	0.811402923327268	183/5600	2
WP581	EPO receptor signaling	2/641	25/5963	0.767003936977813	0.999999278479011	0.811402923327268	8651/6772	2
WP5037	Riboflavin and CoQ disorders	1/641	13/5963	0.772361584780561	0.999999278479011	0.811402923327268	55065	1
WP304	Kit receptor signaling pathway	5/641	59/5963	0.775228675126397	0.999999278479011	0.811402923327268	3726/4067/6615/8651/6772	5
WP3931	Embryonic stem cell pluripotency pathways	8/641	91/5963	0.77669305315043	0.999999278479011	0.811402923327268	2255/2252/2254/6300/5159/7480/7472/7474	8
WP1422	Sphingolipid pathway	2/641	26/5963	0.785876813336648	0.999999278479011	0.811402923327268	56624/8877	2
WP241	One-carbon metabolism	2/641	26/5963	0.785876813336648	0.999999278479011	0.811402923327268	2346/2745	2
WP4875	Disruption of postsynaptic signaling by CNV	2/641	26/5963	0.785876813336648	0.999999278479011	0.811402923327268	2906/9378	2
WP2272	Pathogenic Escherichia coli infection	4/641	49/5963	0.787713110055106	0.999999278479011	0.811402923327268	9076/23643/10381/84617	4
WP4758	Nephrotic syndrome	3/641	38/5963	0.791423557552027	0.999999278479011	0.811402923327268	8542/1493/8029	3
WP710	DNA damage response (only ATM dependent)	9/641	103/5963	0.791805940926473	0.999999278479011	0.811402923327268	8061/3949/5288/8503/5328/6648/7480/7472/7474	9
WP3969	H19 action Rb-E2F1 signaling and CDK-Beta-catenin activity	1/641	14/5963	0.796885319932773	0.999999278479011	0.811402923327268	283120	1
WP4584	Biomarkers for pyrimidine metabolism disorders	1/641	14/5963	0.796885319932773	0.999999278479011	0.811402923327268	1890	1
WP47	Hedgehog signaling pathway	1/641	14/5963	0.796885319932773	0.999999278479011	0.811402923327268	6469	1
WP3915	Angiopoietin-like protein 8 regulatory pathway	11/641	125/5963	0.801757271873567	0.999999278479011	0.811402923327268	64240/64241/1555/1576/1734/1326/5600/6300/5288/8503/6319	11
WP536	Calcium regulation in cardiac cells	11/641	125/5963	0.801757271873567	0.999999278479011	0.811402923327268	775/2701/2702/2709/10052/2786/3760/5350/6004/5999/8490	11
WP2112	IL-17 signaling pathway	2/641	27/5963	0.803392063278888	0.999999278479011	0.811402923327268	1051/3605	2
WP2525	Trans-sulfuration and one-carbon metabolism	2/641	27/5963	0.803392063278888	0.999999278479011	0.811402923327268	875/29968	2
WP2533	Glycerophospholipid biosynthetic pathway	2/641	27/5963	0.803392063278888	0.999999278479011	0.811402923327268	2819/5320	2
WP5085	Vasopressin-regulated water reabsorption	3/641	39/5963	0.805998997485065	0.999999278479011	0.811402923327268	398/84699/9586	3
WP1772	Apoptosis modulation and signaling	7/641	84/5963	0.813212721960866	0.999999278479011	0.811402923327268	597/330/664/834/843/8739/8794	7
WP1946	Cori cycle	1/641	15/5963	0.818770764532385	0.999999278479011	0.811402923327268	6514	1
WP2291	Deregulation of Rab and Rab effector genes in bladder cancer	1/641	15/5963	0.818770764532385	0.999999278479011	0.811402923327268	201294	1
WP4962	Airway smooth muscle cell contraction	1/641	15/5963	0.818770764532385	0.999999278479011	0.811402923327268	952	1
WP5101	Congenital generalized lipodystrophy (CGL)	1/641	15/5963	0.818770764532385	0.999999278479011	0.811402923327268	3091	1
WP4481	Resistin as a regulator of inflammation	2/641	28/5963	0.819622972020135	0.999999278479011	0.811402923327268	3569/7124	2
WP5038	Mitochondrial immune response to SARS-CoV-2	2/641	28/5963	0.819622972020135	0.999999278479011	0.811402923327268	1636/59272	2
WP3940	One-carbon metabolism and related pathways	3/641	40/5963	0.819707709841377	0.999999278479011	0.811402923327268	64902/586/6648	3
WP4222	Phosphodiesterases in neuronal function	3/641	40/5963	0.819707709841377	0.999999278479011	0.811402923327268	2906/10846/5142	3
WP4630	Measles virus infection	10/641	117/5963	0.82211563605251	0.999999278479011	0.811402923327268	3310/3552/3553/3559/3569/4939/8503/6504/6772/7097	10
WP314	Fas ligand pathway and stress induction of heat shock proteins	3/641	41/5963	0.832583571967276	0.999999278479011	0.811402923327268	843/3552/7124	3
WP4290	Metabolic reprogramming in colon cancer	3/641	41/5963	0.832583571967276	0.999999278479011	0.811402923327268	229/3101/29968	3
WP49	IL-2 signaling pathway	3/641	41/5963	0.832583571967276	0.999999278479011	0.811402923327268	3559/9021/6772	3
WP3972	PDGFR-beta pathway	2/641	29/5963	0.834642779161837	0.999999278479011	0.811402923327268	5159/6772	2
WP22	IL-9 signaling pathway	1/641	16/5963	0.838301352954501	0.999999278479011	0.811402923327268	6772	1
WP4815	Glycosaminoglycan degradation	1/641	16/5963	0.838301352954501	0.999999278479011	0.811402923327268	3373	1
WP4970	Galanin receptor pathway	1/641	16/5963	0.838301352954501	0.999999278479011	0.811402923327268	3569	1
WP4321	Thermogenesis	8/641	98/5963	0.841380526666787	0.999999278479011	0.811402923327268	2180/2182/126129/84699/9586/5600/6300/5593	8
WP2572	Primary focal segmental glomerulosclerosis (FSGS)	5/641	65/5963	0.842623236720341	0.999999278479011	0.811402923327268	941/9076/22943/4311/5329	5
WP195	IL-1 signaling pathway	4/641	54/5963	0.847087722638562	0.999999278479011	0.811402923327268	6347/3552/3553/11213	4
WP143	Fatty acid beta-oxidation	2/641	30/5963	0.848523842800218	0.999999278479011	0.811402923327268	2180/2182	2
WP3858	Toll-like receptor signaling related to MyD88	2/641	30/5963	0.848523842800218	0.999999278479011	0.811402923327268	7097/51311	2
WP1982	Sterol regulatory element-binding proteins (SREBP) signaling	5/641	66/5963	0.852061629596559	0.999999278479011	0.811402923327268	3638/3949/4597/6319/6713	5
WP5027	nsp1 from SARS-CoV-2 inhibits translation initiation in the host cell	1/641	17/5963	0.855730112456126	0.999999278479011	0.811402923327268	728689	1
WP5200	Dravet syndrome	1/641	17/5963	0.855730112456126	0.999999278479011	0.811402923327268	5600	1
WP1971	Integrated cancer pathway	3/641	43/5963	0.855976698875743	0.999999278479011	0.811402923327268	994/4312/6772	3
WP2636	Common pathways underlying drug addiction	2/641	31/5963	0.861336983370188	0.999999278479011	0.811402923327268	72/2893	2
WP4871	Kisspeptin/kisspeptin receptor system in the ovary	2/641	31/5963	0.861336983370188	0.999999278479011	0.811402923327268	3283/4318	2
WP2064	Neural crest differentiation	5/641	68/5963	0.869529856518384	0.999999278479011	0.811402923327268	4488/4854/4855/6615/7291	5
WP3670	Interactions between LOXL4 and oxidative stress pathway	1/641	18/5963	0.871282920716405	0.999999278479011	0.811402923327268	2252	1
WP4301	Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells	1/641	18/5963	0.871282920716405	0.999999278479011	0.811402923327268	22808	1
WP4217	Ebola virus infection in host	10/641	124/5963	0.87185989081247	0.999999278479011	0.811402923327268	432/684/93978/2318/3119/3134/3678/8503/9021/6772	10
WP3995	Prion disease pathway	2/641	32/5963	0.87315097833615	0.999999278479011	0.811402923327268	10538/6688	2
WP4542	Leukocyte-intrinsic Hippo pathway functions	2/641	32/5963	0.87315097833615	0.999999278479011	0.811402923327268	50943/639	2
WP231	TNF-alpha signaling pathway	7/641	92/5963	0.878896631926193	0.999999278479011	0.811402923327268	330/6347/3569/1326/6401/7124/7185	7
WP3529	Zinc homeostasis	2/641	33/5963	0.884032182960926	0.999999278479011	0.811402923327268	7780/169026	2
WP4874	CAMKK2 pathway	2/641	33/5963	0.884032182960926	0.999999278479011	0.811402923327268	3383/4094	2
WP4880	Host-pathogen interaction of human coronaviruses - interferon induction	2/641	33/5963	0.884032182960926	0.999999278479011	0.811402923327268	4939/6772	2
WP4396	Nonalcoholic fatty liver disease	11/641	137/5963	0.884429316008629	0.999999278479011	0.811402923327268	6347/84701/3552/3553/3569/56901/9971/8503/5313/9021/7124	11
WP4142	Metabolism of spingolipids in ER and Golgi apparatus	1/641	19/5963	0.885161414883064	0.999999278479011	0.811402923327268	8877	1
WP4206	Hereditary leiomyomatosis and renal cell carcinoma pathway	1/641	19/5963	0.885161414883064	0.999999278479011	0.811402923327268	3091	1
WP5103	Progeria-associated lipodystrophy	1/641	19/5963	0.885161414883064	0.999999278479011	0.811402923327268	2200	1
WP5194	Synthesis of ceramides and 1-deoxyceramides	1/641	19/5963	0.885161414883064	0.999999278479011	0.811402923327268	8877	1
WP400	p38 MAPK signaling pathway	2/641	34/5963	0.894044255953651	0.999999278479011	0.811402923327268	6772/7042	2
WP2507	Nanomaterial induced apoptosis	1/641	20/5963	0.897545589354793	0.999999278479011	0.811402923327268	5551	1
WP3657	Hematopoietic stem cell gene regulation by GABP alpha/beta complex	1/641	20/5963	0.897545589354793	0.999999278479011	0.811402923327268	3002	1
WP4725	Sphingolipid metabolism overview	1/641	20/5963	0.897545589354793	0.999999278479011	0.811402923327268	8877	1
WP4262	Breast cancer pathway	10/641	129/5963	0.900025856688474	0.999999278479011	0.811402923327268	2255/2252/2254/11211/4854/4855/8503/7480/7472/7474	10
WP4288	MTHFR deficiency	1/641	21/5963	0.908596115557649	0.999999278479011	0.811402923327268	2906	1
WP4726	Sphingolipid metabolism: integrated pathway	1/641	21/5963	0.908596115557649	0.999999278479011	0.811402923327268	8877	1
WP4905	1q21.1 copy number variation syndrome	1/641	21/5963	0.908596115557649	0.999999278479011	0.811402923327268	2702	1
WP2637	Interleukin-1 (IL-1) structural pathway	3/641	49/5963	0.909829155899699	0.999999278479011	0.811402923327268	3552/1326/5600	3
WP2447	Amyotrophic lateral sclerosis (ALS)	2/641	36/5963	0.91170110495043	0.999999278479011	0.811402923327268	834/7124	2
WP3850	Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling	2/641	36/5963	0.91170110495043	0.999999278479011	0.811402923327268	3488/8744	2
WP623	Oxidative phosphorylation	2/641	36/5963	0.91170110495043	0.999999278479011	0.811402923327268	3002/56901	2
WP4932	7q11.23 copy number variation syndrome	6/641	86/5963	0.912627359793194	0.999999278479011	0.811402923327268	9076/2200/3224/5313/9246/7472	6
WP2037	Prolactin signaling pathway	5/641	75/5963	0.917549144367809	0.999999278479011	0.811402923327268	3659/4843/8651/9021/6772	5
WP3872	Regulation of apoptosis by parathyroid hormone-related protein	1/641	22/5963	0.918456413424958	0.999999278479011	0.811402923327268	597	1
WP4537	Hippo-Yap signaling pathway	1/641	22/5963	0.918456413424958	0.999999278479011	0.811402923327268	3627	1
WP4148	Splicing factor NOVA regulated synaptic proteins	2/641	37/5963	0.919458370900061	0.999999278479011	0.811402923327268	1600/2898	2
WP4249	Hedgehog signaling pathway	2/641	37/5963	0.919458370900061	0.999999278479011	0.811402923327268	2619/6469	2
WP500	Glycogen synthesis and degradation	2/641	38/5963	0.926571416086063	0.999999278479011	0.811402923327268	3099/3101	2
WP3658	Wnt/beta-catenin signaling pathway in leukemia	1/641	23/5963	0.927254501119723	0.999999278479011	0.811402923327268	22943	1
WP3982	miRNA regulation of p53 pathway in prostate cancer	1/641	23/5963	0.927254501119723	0.999999278479011	0.811402923327268	5054	1
WP4541	Hippo-Merlin signaling dysregulation	7/641	101/5963	0.928625403392001	0.999999278479011	0.811402923327268	1001/1003/3627/3678/3687/3689/5159	7
WP4906	3q29 copy number variation syndrome	3/641	52/5963	0.929244737186931	0.999999278479011	0.811402923327268	3091/8503/200931	3
WP2355	Corticotropin-releasing hormone signaling pathway	5/641	78/5963	0.932837696928289	0.999999278479011	0.811402923327268	8061/3283/3726/4929/6822	5
WP2526	PDGF pathway	2/641	39/5963	0.933088844118549	0.999999278479011	0.811402923327268	5159/6772	2
WP585	Interferon type I signaling pathways	3/641	53/5963	0.934811117764962	0.999999278479011	0.811402923327268	8651/9021/6772	3
WP4521	Glycosylation and related congenital defects	1/641	24/5963	0.935104646705962	0.999999278479011	0.811402923327268	79644	1
WP4925	Unfolded protein response	1/641	24/5963	0.935104646705962	0.999999278479011	0.811402923327268	3553	1
WP4941	GPR143 in melanocytes and retinal pigment epithelium cells	1/641	24/5963	0.935104646705962	0.999999278479011	0.811402923327268	2769	1
WP5124	Alzheimer's disease	18/641	226/5963	0.936502032584863	0.999999278479011	0.811402923327268	775/22943/11211/2906/3552/3553/3569/3800/4311/4843/8503/5743/7124/10381/84617/7480/7472/7474	18
WP4312	Rett syndrome causing genes	2/641	40/5963	0.9390562722384	0.999999278479011	0.811402923327268	3766/23221	2
WP1544	MicroRNAs in cardiomyocyte hypertrophy	5/641	80/5963	0.941571541952973	0.999999278479011	0.811402923327268	183/8503/5320/7124/7474	5
WP2059	Alzheimer's disease and miRNA effects	18/641	229/5963	0.944352265194109	0.999999278479011	0.811402923327268	775/22943/11211/2906/3552/3553/3569/3800/4311/4843/8503/5743/7124/10381/84617/7480/7472/7474	18
WP268	Notch signaling	2/641	41/5963	0.944516410713842	0.999999278479011	0.811402923327268	4854/4855	2
WP2817	Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4)	1/641	26/5963	0.948358124128954	0.999999278479011	0.811402923327268	1051	1
WP4806	EGFR tyrosine kinase inhibitor resistance	5/641	82/5963	0.949269856701312	0.999999278479011	0.811402923327268	3082/3569/22808/5159/8503	5
WP4534	Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms	2/641	42/5963	0.94950915967617	0.999999278479011	0.811402923327268	72/3689	2
WP4535	Envelope proteins and their potential roles in EDMD physiopathology	2/641	42/5963	0.94950915967617	0.999999278479011	0.811402923327268	7042/7043	2
WP61	Notch signaling pathway	3/641	57/5963	0.953269261251194	0.999999278479011	0.811402923327268	3091/4854/4855	3
WP3996	Ethanol effects on histone modifications	1/641	27/5963	0.953933741853957	0.999999278479011	0.811402923327268	8854	1
WP4856	Intracellular trafficking proteins involved in CMT neuropathy	1/641	27/5963	0.953933741853957	0.999999278479011	0.811402923327268	1959	1
WP5102	Familial partial lipodystrophy (FPLD)	1/641	27/5963	0.953933741853957	0.999999278479011	0.811402923327268	5396	1
WP5121	Sphingolipid metabolism in senescence	1/641	27/5963	0.953933741853957	0.999999278479011	0.811402923327268	8877	1
WP4255	Non-small cell lung cancer	4/641	71/5963	0.955601419278835	0.999999278479011	0.811402923327268	1381/1382/8503/6258	4
WP1403	AMP-activated protein kinase (AMPK) signaling	3/641	58/5963	0.957052928065658	0.999999278479011	0.811402923327268	126129/5209/8503	3
WP2038	Microtubule cytoskeleton regulation	2/641	44/5963	0.958238705547047	0.999999278479011	0.811402923327268	2151/11076	2
WP2583	T cell receptor and co-stimulatory signaling	1/641	28/5963	0.958908214810765	0.999999278479011	0.811402923327268	1493	1
WP183	Proteasome degradation	3/641	59/5963	0.960548323131835	0.999999278479011	0.811402923327268	3134/3458/5698	3
WP5072	Modulators of TCR signaling and T cell activation	3/641	59/5963	0.960548323131835	0.999999278479011	0.811402923327268	3937/1326/8651	3
WP1601	Fluoropyrimidine activity	1/641	29/5963	0.963346266083941	0.999999278479011	0.811402923327268	1890	1
WP722	Serotonin HTR1 group and FOS pathway	1/641	29/5963	0.963346266083941	0.999999278479011	0.811402923327268	3352	1
WP2118	Arrhythmogenic right ventricular cardiomyopathy	3/641	60/5963	0.963775389749444	0.999999278479011	0.811402923327268	775/1496/3678	3
WP4566	Translation inhibitors in chronically activated PDGFRA cells	2/641	46/5963	0.965512272014334	0.999999278479011	0.811402923327268	8503/11040	2
WP2363	Gastric cancer network 2	1/641	30/5963	0.967305659990277	0.999999278479011	0.811402923327268	51316	1
WP3844	PI3K-AKT-mTOR signaling pathway and therapeutic opportunities	1/641	30/5963	0.967305659990277	0.999999278479011	0.811402923327268	8503	1
WP2034	Leptin signaling pathway	4/641	75/5963	0.96753185827163	0.999999278479011	0.811402923327268	3553/3557/9021/6772	4
WP3998	Prader-Willi and Angelman syndrome	1/641	32/5963	0.97398914181981	0.999999278479011	0.811402923327268	2562	1
WP3888	VEGFA-VEGFR2 signaling pathway	33/641	409/5963	0.97457915605383	0.999999278479011	0.811402923327268	56999/301/6347/1003/79094/1558/22943/1847/1960/2022/24147/6624/1839/3383/6300/4319/4313/4688/4855/4929/8013/5228/5328/5329/5743/27289/57758/6401/9047/6648/6772/8794/81567	33
WP244	Alpha 6 beta 4 signaling pathway	1/641	33/5963	0.976800296784151	0.999999278479011	0.811402923327268	3918	1
WP3981	miRNA regulation of prostate cancer signaling pathways	1/641	33/5963	0.976800296784151	0.999999278479011	0.811402923327268	5159	1
WP422	MAPK cascade	1/641	33/5963	0.976800296784151	0.999999278479011	0.811402923327268	6300	1
WP3286	Copper homeostasis	2/641	51/5963	0.978755504607089	0.999999278479011	0.811402923327268	79689/54739	2
WP185	Integrin-mediated cell adhesion	5/641	94/5963	0.979068494936225	0.999999278479011	0.811402923327268	11131/3678/3687/3689/6300	5
WP313	Hepatocyte growth factor receptor signaling	1/641	34/5963	0.979308055597196	0.999999278479011	0.811402923327268	3082	1
WP4659	Gastrin signaling pathway	6/641	108/5963	0.980396957198751	0.999999278479011	0.811402923327268	330/9076/4316/8503/5743/5054	6
WP2795	Cardiac hypertrophic response	2/641	53/5963	0.982536908540716	0.999999278479011	0.811402923327268	5320/7124	2
WP4205	MET in type 1 papillary renal cell carcinoma	2/641	53/5963	0.982536908540716	0.999999278479011	0.811402923327268	3082/8503	2
WP4223	Ras signaling	10/641	161/5963	0.983877817456673	0.999999278479011	0.811402923327268	2786/22808/5159/8503/51365/84647/5320/50487/283748/115727	10
WP4216	Chromosomal and microsatellite instability in colorectal cancer 	3/641	70/5963	0.984907198467113	0.999999278479011	0.811402923327268	5743/7042/7043	3
WP524	G13 signaling pathway	1/641	37/5963	0.985320723669197	0.999999278479011	0.811402923327268	398	1
WP35	G protein signaling pathways	4/641	85/5963	0.985575871612868	0.999999278479011	0.811402923327268	2769/2786/3760/5142	4
WP3584	MECP2 and associated Rett syndrome	2/641	56/5963	0.987013008096382	0.999999278479011	0.811402923327268	2893/6890	2
WP51	Regulation of actin cytoskeleton	7/641	127/5963	0.987306081103576	0.999999278479011	0.811402923327268	2255/2252/2254/22808/5159/5288/8503	7
WP4263	Pancreatic adenocarcinoma pathway	4/641	87/5963	0.987791005548495	0.999999278479011	0.811402923327268	8503/6772/7042/7043	4
WP366	TGF-beta signaling pathway	7/641	130/5963	0.989764294209671	0.999999278479011	0.811402923327268	467/1278/50943/3726/4312/4321/3371	7
WP2853	Endoderm differentiation	6/641	118/5963	0.990670614936897	0.999999278479011	0.811402923327268	22943/1846/1847/3227/6772/30009	6
WP4155	Endometrial cancer	2/641	61/5963	0.992112946083689	0.999999278479011	0.811402923327268	1496/8503	2
WP4971	Phosphoinositides metabolism	1/641	44/5963	0.993415826735444	0.999999278479011	0.811402923327268	5288	1
WP2032	Thyroid stimulating hormone (TSH) signaling pathway	2/641	64/5963	0.994168994348518	0.999999278479011	0.811402923327268	6772/7253	2
WP4540	Hippo signaling regulation pathways	3/641	84/5963	0.99580963231329	0.999999278479011	0.811402923327268	1001/1003/5159	3
WP107	Translation factors	1/641	49/5963	0.996288774676289	0.999999278479011	0.811402923327268	728689	1
WP2380	Brain-derived neurotrophic factor (BDNF) signaling pathway	6/641	134/5963	0.997335347340708	0.999999278479011	0.811402923327268	249/1959/2562/4688/6696/6772	6
WP2857	Mesodermal commitment pathway	5/641	122/5963	0.997825510733332	0.999999278479011	0.811402923327268	8553/22943/2296/3624/6615	5
WP481	Insulin signaling	7/641	156/5963	0.998580463383844	0.999999278479011	0.811402923327268	1326/5600/6300/5288/8503/8651/9021	7
WP3680	Physico-chemical features and toxicity-associated pathways	1/641	58/5963	0.998679362315039	0.999999278479011	0.811402923327268	11211	1
WP4022	Pyrimidine metabolism	2/641	79/5963	0.99874532596887	0.999999278479011	0.811402923327268	956/1890	2
WP2261	Glioblastoma signaling pathways	2/641	82/5963	0.99908136158936	0.999999278479011	0.811402923327268	5159/5288	2
WP45	G1 to S cell cycle control	1/641	62/5963	0.99916610025139	0.999999278479011	0.811402923327268	84699	1
WP673	ErbB signaling pathway	2/641	83/5963	0.999172268081107	0.999999278479011	0.811402923327268	1839/8503	2
WP4685	Melanoma	1/641	63/5963	0.999256683159178	0.999999278479011	0.811402923327268	8503	1
WP437	EGF/EGFR signaling pathway	6/641	157/5963	0.999607637819849	0.999999278479011	0.811402923327268	9046/7837/9047/6456/6772/7291	6
WP4656	Joubert syndrome	1/641	71/5963	0.999703972672158	0.999999278479011	0.811402923327268	6469	1
WP23	B cell receptor signaling pathway	2/641	96/5963	0.999788947822422	0.999999278479011	0.811402923327268	27071/4067	2
WP179	Cell cycle	3/641	115/5963	0.999791150957675	0.999999278479011	0.811402923327268	994/7042/7043	3
WP138	Androgen receptor signaling pathway	1/641	85/5963	0.999941085581571	0.999999278479011	0.811402923327268	8431	1
WP2446	Retinoblastoma gene in cancer	1/641	86/5963	0.999947510239995	0.999999278479011	0.811402923327268	994	1
WP4549	Fragile X syndrome	1/641	101/5963	0.999990736347898	0.999999278479011	0.811402923327268	4318	1
WP4803	Ciliopathies	2/641	139/5963	0.999997962833273	0.999999278479011	0.811402923327268	122481/10309	2
WP4352	Ciliary landscape	5/641	201/5963	0.999998521562279	0.999999278479011	0.811402923327268	875/30845/3934/2040/339488	5
WP411	mRNA processing	1/641	123/5963	0.999999278479011	0.999999278479011	0.811402923327268	10772	1
